Evogene is to receive $3.5 million from Bayer through the companies' joint seed traits collaboration agreement, which was originally established between Evogene and Monsanto in 2008. Under the agreement, Evogene provided Bayer with a license to genes discovered to address specific seed traits for use in maize, soybean, cotton, and canola. In 2019, the two companies updated their maize disease resistance research program to focus on the identification of genome editing targets for evaluation against a range of maize diseases (see AgbioNews Jul 16, 2019).